Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02543645 · ClinicalTrials.gov registry record · Phase 1
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase 1 study, sponsored by Celldex Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02543645: Clinical Trial Phase 1 study, sponsored by Celldex Therapeutics.
NCT02543645 is a Phase 1 study that was terminated before completion, run by Celldex Therapeutics. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02543645, a Phase 1 study, was terminated before completion, sponsored by Celldex Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab. Phase l of the study will enroll patients with a number of tumor types; Phase ll will enroll only patients with renal cell carcinoma (RCC).\* \*Note: This Study was terminated prior to initiation of Phase II
Interventions
- DRUG Combination of Varlilumab and Atezolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-05-22 |
| Phase | Phase 1 |
Why NCT02543645 stopped before completion
NCT02543645 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which Combination of Varlilumab and Atezolizumab is the first listed.
NCT02543645 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02543645 about?
NCT02543645 is a clinical study titled "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer". This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab. Phase l of the study will enroll patients with a number of tumor types; Phase ll will enroll only patients with renal cell carcinoma (RCC).\* \*Note: This S...
What is the current status of trial NCT02543645?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2015-10. Estimated completion is 2017-05-22.
What interventions are being tested in trial NCT02543645?
The interventions under investigation include: Combination of Varlilumab and Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT02543645?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02543645's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia